LXRX vs. VSTM, VNDA, XOMA, EBS, MACK, RIGL, RGLS, RZLT, OPK, and INVA Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Emergent BioSolutions (EBS), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Rezolute (RZLT), OPKO Health (OPK), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Verastem (NASDAQ:VSTM ) and Lexicon Pharmaceuticals (NASDAQ:LXRX ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
Verastem presently has a consensus price target of $28.79, suggesting a potential upside of 145.82%. Lexicon Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 177.78%. Given Verastem's higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Verastem.
Verastem has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
In the previous week, Verastem had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Verastem and 5 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.83 beat Verastem's score of 0.48 indicating that Verastem is being referred to more favorably in the media.
Verastem has higher revenue and earnings than Lexicon Pharmaceuticals. Verastem is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -8,311.12%. Verastem's return on equity of -108.54% beat Lexicon Pharmaceuticals' return on equity.
88.4% of Verastem shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 4.5% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Verastem received 130 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 65.17% of users gave Verastem an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
Summary Verastem beats Lexicon Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
